With worldwide prescription drug sales expected to reach $1 trillion by 2020, pharma is poised for dramatic change. Alongside this growth in sales comes challenges such as emerging technologies, new regulatory requirements, and more complex supply chains, to name a few. Even before sales are made, a large proportion of potential profits—now estimated to exceed $2 billion on average—is invested into drug development alone.
The globalization of clinical drug trials has helped reduce costs and speed time-to-market, making quality translation a vital component in meeting new challenges. However, when organizations are managing several multilingual clinical trials, facing resourcing pressures, or in an active M&A environment, it can be difficult to achieve efficiency in both localization and core internal processes.
The answer? Centralization.
Centralization is an increasingly popular best practice for end-to-end localization management, especially in the context of multilingual clinical labeling, a critical component of global trials. See the infographic below for a quick overview of its benefits (our eBook, Global Regulatory Solutions: Clinical Labeling Services, describes these and multilingual clinical labeling processes in more detail).
Global Clinical Trials
Clinical trials are currently underway in 200+ countries.
Almost half take place outside of the U.S., including emerging countries who are heavily investing in healthcare and life sciences infrastructure.
Testing and approval are now set upon a global path, which serves both developers and diverse patient populations.
The move to globalization has made accurate and effective multilingual clinical labeling critical to meeting patient, clinician, supply chain, and regulatory needs.
WARNING: Clinical label translation and compliance mistakes are costly and can jeopardize your entire trial.
Critical challenges for multilingual clinical label management
- Shorter production timelines for a greater variety of label types, in more languages
- Errors & inconsistencies from multiple vendors across multisite studies lead to regulatory mistakes and translation errors
- Demanding process with 1000s of moving parts can overwhelm the most robust organizations
- Streamline multiple vendors & processes
- Speed turnaround times
- Reduce cost and risk
- Increase total quality
- Remove internal distractions
Streamlined, scalable process for global clinical trials
- Greater efficiencies – optimized process for speed, scale, quality
- Patient health – accuracy and consistency for 250+ languages
- Financial savings – labels and submissions right the first time
Learn more at lifesciences.lionbridge.com